✦ LIBER ✦

A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer

✍ Scribed by W. Fiedler; N. Tchen; J. Bloch; P. Fargeot; R. Sorio; J.B. Vermorken; L. Collette; D. Lacombe; C. Twelves

Book ID: 116428699
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 116 KB
Volume: 42
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2005.07.030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A clinical phase II study with sorafenib

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

✍ Steinbild, S; Mross, K; Frost, A; Morant, R; Gillessen, S; Dittrich, C; Strumber 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 123 KB

A phase II study of fenretinide in patie

A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group

✍ M. M. Moore; M. Stockler; R. Lim; T. S. K. Mok; M. Millward; M. J. Boyer 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 228 KB

The Canadian Uro-Oncology Group multicen

The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone

✍ Fred Saad; Dean Ruether; Scott Ernst; Scott North; Tina Cheng; Paul Perrotte; Pi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

Weekly administration of docetaxel in co

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

✍ Carles, J; Font, A; Mellado, B; Domenech, M; Gallardo, E; González-Larriba, J L; 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 113 KB

A Phase II study of estramustine, doceta

A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813

✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,

Clinical Outcomes of a Phase II Open-lab

Clinical Outcomes of a Phase II Open-labelled, Randomised Study Investigating the Tolerability and Efficacy of Anti-androgen Manipulation versus Taxotere and Anti-androgen Manipulation in Patients with Hormone Naive High Risk/Metastatic Prostate Cancer

✍ J. Wilson; A.B. Al-Naeeb; A.R.A. Razak; J.A. Frew; A. Azzabi; R. McMenemin; N. S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB